Recent

% | $
Quotes you view appear here for quick access.

Illumina Inc. Message Board

gadzillionman 129 posts  |  Last Activity: 3 hours ago Member since: Feb 19, 2004
  • Reply to

    This is the way I see it...

    by biohitechinvestor Apr 22, 2016 8:26 AM
    gadzillionman gadzillionman Apr 24, 2016 10:45 AM Flag

    It works most of the time but sure wish I could use my 25 years of experience in the stock market to make better trades, I've only made 1.3m so guess I should buy a higher quality crystal ball next time & stop being such a loser!! A few of my other longs is PACB & CPXX & will most likely lose a lot of money on them.

  • gadzillionman gadzillionman Apr 22, 2016 10:48 AM Flag

    We are on the same team, just trying to be realistic , I've got 6 figures invested so I'm all for a higher price,but seeing that article about company only worth 1b is a joke as that would imply $6-7 a share which is just ridiculous !!

  • Reply to

    This is the way I see it...

    by biohitechinvestor Apr 22, 2016 8:26 AM
    gadzillionman gadzillionman Apr 22, 2016 10:30 AM Flag

    When I first bought SGYP it was @ $3.90 & we know way way more more about this company, so why does the stock trade @ 3.60 ?? to your point we should be @ 10+ today but we are not, I hope your right that this will fly but only if we get multiple bids, I still say not more than $12 & lets hope that is all cash & not stock because I personally don't want to wait 3-4 months to tender my shares!! PS: How do we get above $12 with high debt,warrants, convertibles etc ??

  • Synergy Pharmaceuticals Inc (SGYP) Given Buy Rating at Rodman & Renshaw

    Posted by paymon on Apr 22nd, 2016 // No Comments

    Synergy Pharmaceuticals Inc logoRodman & Renshaw reiterated their buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) in a research report released on Thursday morning, MarketBeat reports. The brokerage currently has a $16.00 target price on the biopharmaceutical company’s stock.

    Several large investors have recently bought and sold shares of SGYP. California State Teachers Retirement System raised its stake in Synergy Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 185,372 shares of the biopharmaceutical company’s stock valued at $1,051,000 after buying an additional 3,251 shares in the last quarter. Allianz Asset Management AG raised its stake in Synergy Pharmaceuticals by 1.6% in the fourth quarter. Allianz Asset Management AG now owns 896,296 shares of the biopharmaceutical company’s stock valued at $5,082,000 after buying an additional 14,429 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Synergy Pharmaceuticals by 7.4% in the fourth quarter. Ameriprise Financial Inc. now owns 312,259 shares of the biopharmaceutical company’s stock valued at $1,770,000 after buying an additional 21,591 shares in the last quarter. Morgan Stanley raised its stake in Synergy Pharmaceuticals by 6.8% in the fourth quarter. Morgan Stanley now owns 423,520 shares of the biopharmaceutical company’s stock valued at $2,401,000 after buying an additional 27,037 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in Synergy Pharmaceuticals by 10.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 342,232 shares of the biopharmaceutical company’s stock valued at $1,941,000 after buying an additional 33,129 shares in the last quarter.

    Synergy Pharmaceuticals (NASDAQ:SGYP) opened at 3.62 on Thursda

    Sentiment: Buy

  • Reply to

    This is the way I see it...

    by biohitechinvestor Apr 22, 2016 8:26 AM
    gadzillionman gadzillionman Apr 22, 2016 9:44 AM Flag

    I have followed SGYP stock for over a year & it was a pipe dream that investors would get $18-25 in a BO, I'm 100% positive that SGYP will be sold sometime after Aug 2016 which is when the final results are due out for IBS-C, not sure why buyer would make bid before this. I do not see a BO price above $10 but with multiple bidders we may see upwards of $12 but not a dime more. Long SGYP

    Sentiment: Buy

  • Even a 1 for 5 reverse split would be devastating to shareholders, do hope company uses other methods?

    Sentiment: Hold

  • Allergan was also rumored late last week to be interested in acquiring Synergy Pharmaceuticals (SGYP). Synergy has filed has an NDA (New Drug Application) for its compound Plecanatide for the treatment of chronic idiopathic constipation which is expected to be approved soon. The product will likely be aimed at the same market as Linzess, a drug it has demonstrated some superior attributes to in trials. Ironwood Pharmaceuticals' (IRWD) Linzess currently does $450 million in annual sales and Ironwood believes it can be a $1 billion drug by 2020. With an enterprise value of just over $400 million, Synergy would be a potential bite-sized purchase for Allergan. Author Bret Jensen 04/18/16

    Sentiment: Strong Buy

  • I see upwards of $15 but doubt much higher, I plan on adding to my position Mon.

    Sentiment: Strong Buy

  • Allergan (AGN) Takeover of Synergy Pharmaceuticals (SGYP) May be Imminent - Source
    April 15, 2016 3:13 PM EDT Send to a Friend
    Allergan (NYSE: AGN) is in advanced talks to acquire Synergy Pharmaceuticals (Nasdaq: SGYP), according ...

    Sentiment: Strong Buy

  • Teva's 40b bid for AGN's generic drug business is not final & may not pass US regulators , I see AGN stock falling $100 !! Hasn't everyone learned lessons from Valeant & Sunedison ??? companies today that has huge debt will not survive long term, its only a legal Ponzi scheme when companies are not responsible with investors money, & they wont be taking mine.

    Sentiment: Strong Sell

  • gadzillionman by gadzillionman Apr 16, 2016 9:13 AM Flag

    I see another Valeant in the making with 42b in debt.

    Sentiment: Strong Sell

  • gadzillionman gadzillionman Apr 15, 2016 9:27 AM Flag

    Already posted this info 2 days ago, way to be on top of things!!!

  • gadzillionman gadzillionman Apr 13, 2016 2:46 PM Flag

    I first bought SGYP @ 3.90 before a lot of milestones was achieved & with all that is known its only @ 3 now !! ? something very wrong, SGYP should be valued today for @ least $8.

  • gadzillionman gadzillionman Apr 13, 2016 2:29 PM Flag

    Any investor would love to sell their shares for $16, & your analysis is logical although $12 is the average for a BO . Shire did try & buy IRWD last year for 3.7b or $30 a share, & I believe they offered SGYP $8.50 a share soon after, but there is still the NDA that hasn't been accepted & the other that hasn't even been filed yet , also final P3 results for IBS-C not due till Aug 2016. Would be surprised to hear of a BO offer before any of this is known.

    Sentiment: Strong Buy

  • Shire's Commercial Portfolio

    Product

    Indication

    Treatment Space

    Q2 Revenue - Q/Q Growth

    Vyvanse Binge Eating Disorder CNS $425M (+18%)
    Lialda Ulcerative Colitis GI $158M (+10%)
    Elaprase Hunter Syndrome GI $147M (-4%)
    Cinryze Hereditary Angioedema Specialty $139M (+7%)
    Replagal Fabry Disease Specialty $117M (-10%)
    Firazyr Acute HAE
    Specialty
    $104M (+17%)
    Adderall XR ADHD CNS $86M (-14%)
    Vpriv Gaucher Disease Specialty $85M (-6%)
    Pentasa Ulcerative Colitis GI $66M (+5%)
    Gattex Short Bowel Syndrome GI $37M (N/A)
    Intuniv ADHD CNS $9M (-91%)
    Other ---- ---- $97M (-13%)
    Total Sales ---- ---- $1.47B (+0%)

    Sentiment: Strong Buy

  • gadzillionman gadzillionman Apr 12, 2016 1:23 PM Flag

    Drug Review Steps Simplified
    1.Preclinical (animal) testing.
    2.An investigational new drug application (IND) outlines what the sponsor of a new drug proposes for human testing in clinical trials.
    3.Phase 1 studies (typically involve 20 to 80 people).
    4.Phase 2 studies (typically involve a few dozen to about 300 people).
    5.Phase 3 studies (typically involve several hundred to about 3,000 people).
    6.The pre-NDA period, just before a new drug application (NDA) is submitted. A common time for the FDA and drug sponsors to meet.
    7.Submission of an NDA is the formal step asking the FDA to consider a drug for marketing approval.
    8.After an NDA is received, the FDA has 60 days to decide whether to file it so it can be reviewed.
    9.If the FDA files the NDA, an FDA review team is assigned to evaluate the sponsor's research on the drug's safety and effectiveness.
    10.The FDA reviews information that goes on a drug's professional labeling (information on how to use the drug).
    11.The FDA inspects the facilities where the drug will be manufactured as part of the approval process.
    12.FDA reviewers will approve the application or issue a complete response letter.

  • Reply to

    HZNP might be a good buyer for ATRS.

    by icantrade200 Apr 12, 2016 12:56 PM
    gadzillionman gadzillionman Apr 12, 2016 1:06 PM Flag

    I always thought Pfizer would eventually buy them , but @ this point I just hope someone does soon, have been in ATRS way too long & no one wants to see a reverse split !!

    Sentiment: Hold

  • Bumps in the Road

    If the FDA decides that the benefits of a drug outweigh the known risks, the drug will receive approval and can be marketed in the United States. But if there are problems with an NDA or if more information is necessary to make that determination, the FDA may issue a complete response letter.

    Common problems include unexpected safety issues that crop up or failure to demonstrate a drug's effectiveness. A sponsor may need to conduct additional studies--perhaps studies of more people, different types of people, or for a longer period of time.

    Manufacturing issues are also among the reasons that approval may be delayed or denied. Drugs must be manufactured in accordance with standards called good manufacturing practices, and the FDA inspects manufacturing facilities before a drug can be approved. If a facility isn't ready for inspection, approval can be delayed. Any manufacturing deficiencies found need to be corrected before approval.

    "Sometimes a company may make a certain amount of a drug for clinical trials. Then when they go to scale up, they may lose a supplier or end up with quality control issues that result in a product of different chemistry," says Kweder. "Sponsors have to show us that the product that's going to be marketed is the same product that they tested."

    John Jenkins, M.D., director of CDER's Office of New Drugs, says, "It's often a combination of problems that prevent approval." Close communication with the FDA early on in a drug's development reduces the chance that an application will have to go through more than one cycle of review, he says. "But it's no guarantee."

    The FDA outlines the justification for its decision in a complete response letter to the drug sponsor and CDER gives the sponsor a chance to meet with agency officials to discuss the deficiencies. At that point, the sponsor can ask for a hearing, correct any deficiencies and submit new information, or withdraw the application.

    Sentiment: Strong Buy

  • This kind of stock requires foresight ,skill, capital & patience to see the trade through, if you don't have these four things combined........ then go buy WMT stock & let the professionals do what we do best!!

    Sentiment: Strong Buy

  • gadzillionman by gadzillionman Apr 11, 2016 12:34 PM Flag

    Linzess flied through all the FDA hurdles & Plecanatide is a far superior drug, so just be patient, also there has been zero cases of adverse effects with IRWD's similar drugs over the past 4 years & that is why SGYP is so de-risked , company still has 50 million in cash, so that's plenty to cut paychecks & wait for buyer!!

    Sentiment: Strong Buy

ILMN
143.48+3.65(+2.61%)May 24 4:00 PMEDT